Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LY01610 in Advanced Solid Tumors
NCT04088604Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Feb 2019
- Primary completion
- Dec 2021
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of irinotecan liposome in solid tumor (advanced stage) (5 arms), sponsored by Luye Pharma Group. Primary endpoints: Dose limiting toxicity and Maximum tolerated dose. Started Feb 2019; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04088604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088604.